Clinical Trial Update: Investigation on Safety, Tolerability, and Pharmacokinetics of Single Doses of NNC0113-0987 in Healthy Male Subjects [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety, tolerability, and pharmacokinetics of single doses of NNC0113-0987 in healthy male volunteers; the trial has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes
• Type 2 Diabetes Mellitus

Drugs mentioned

• NNC0113-0987

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | Status: COMPLETED